Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#3007 An mRNA-based Classifier Identifies PanNETs with Different Clinicopathological Characteristics
Introduction: Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of neoplasms that varies from indolent to highly aggressive diseases. Previous studies have suggested alterations of ATRX/DAXX as biomarkers of dismal prognosis, yet inconclusive data (especially in the metastatic setting) prevent those biomarkers to be used as routine clinical tests.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Vicentini C, Barbi S, Bersani S, Rusev B, Lawlor R,
Keywords: PanNET, gene expression profile, ATRX/DAXX mutations, patients’ stratification.,
Introduction: The driving genetic alteration leading to neuroendocrine tumor (NET) development has been reported for primary tumors of pancreatic origin, but not for metastases. Moreover, even for primary tumor a significant “dark matter” remains to be explored.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Tirosh A
Authors: Tirosh A, Killian J, Zhu Y, Neychev V, Meltzer P,
Keywords: GEP-NET, Driver mutation, Copy-number, Metastases,
Introduction: Patient tumour-derived cell lines have been widely used for studying the molecular mechanisms of tumours and their response to therapy. The establishment of cell lines from gastro-entero-pancreatic neuroendocrine tumours (GEPNETs) has proved difficult, but despite the challenges a limited amount of cell lines now exists.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Hofving T, Arvidsson Y, Almobarak B, Inge L, Pfragner R,
Keywords: neuroendocrine tumor, GEP-NET, immunophenotyping, copy-number alterations, exome sequencing, inhibitor screening, vorinostat, trametinib,